STOCK TITAN

TWST Chief Accounting Officer sold 2,041 shares to cover PSU taxes

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Robert F. Werner, Chief Accounting Officer and director of Twist Bioscience Corp (TWST), reported a non-discretionary sale of 2,041 shares of common stock on 10/06/2025 at a price of $32.187 per share. After the sale, Mr. Werner beneficially owned 46,413 shares. The filing states the shares were sold to satisfy tax-withholding obligations tied to the vesting of Performance Stock Units (PSUs) and were executed under the issuer's mandatory "sell to cover" election, not as voluntary open-market trades. The Form 4 was signed by an attorney-in-fact on 10/08/2025.

Positive

  • Insider retained significant ownership with 46,413 shares remaining after the transaction
  • Sale was non-discretionary and executed to satisfy tax withholding from PSU vesting

Negative

  • []

Insights

Sale was a routine "sell-to-cover" for vested PSUs, not a discretionary trade.

The transaction shows 2,041 shares sold at $32.187 to meet tax withholding from vested Performance Stock Units. A "sell to cover" is a common mechanism where the employer elects to satisfy tax obligations by selling a portion of vested equity.

This reduces the reporting person's outstanding shares by the stated amount and has no disclosed change to ongoing equity incentive terms; monitor upcoming equity vesting schedules and any future Form 4s around scheduled PSU vesting dates within the next 12 months.

Insider remains materially invested with post-sale ownership intact.

After the transaction the reporting person retained 46,413 shares, indicating continued ownership alignment with shareholders. The Form 4 identifies the transaction as directed by the issuer's tax-withholding election, limiting interpretive weight about intent.

Investors often view sell-to-cover differently from discretionary selling; watch for any future reported sales that are not labeled as tax-withholding within the next fiscal year to assess changes in insider conviction.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WERNER ROBERT F.

(Last) (First) (Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Accounting Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/06/2025 S 2,041(1) D $32.187 46,413 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Remarks:
/s/ Kendra Fox, as Attorney-in-Fact for Robert F. Werner 10/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Robert F. Werner report on Form 4 for TWST?

He reported a sale of 2,041 shares on 10/06/2025 at $32.187 per share and a post-transaction beneficial ownership of 46,413 shares.

Why were the 2,041 shares sold according to the filing?

The filing states the shares were sold to satisfy tax withholding obligations related to the vesting of Performance Stock Units (PSUs) under the issuer's mandatory "sell to cover" election.

Was this a discretionary open-market sale?

No. The filing specifies the sale was required by the issuer's election to fund tax withholding and did not represent a discretionary trade by the reporting person.

How much did the shares sell for on 10/06/2025?

The reported sale price was $32.187 per share.

Who signed the Form 4 for Robert F. Werner?

The Form 4 was signed by an attorney-in-fact, Kendra Fox, on 10/08/2025.
Twist Bioscience

NASDAQ:TWST

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data

2.54B
60.26M
1.86%
115.89%
16.96%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO